Dr Tie talks to ecancer at ASCO 2025 about data she presented from the AGITG DYNAMIC-III Trial

The phase II/III trial investigated whether circulating tumor DNA (ctDNA)-guided escalation of adjuvant chemotherapy (ACT) improves recurrence-free survival (RFS) in patients with resected stage III colon cancer who tested ctDNA-positive after surgery.

Among 259 ctDNA-positive patients, escalation to more intensive regimens such as FOLFOXIRI did not result in improved 2-year or 3-year RFS compared to standard care (HR 1.11; P = 0.6), and recurrence risk was found to correlate strongly with ctDNA burden.

These results highlight the prognostic value of ctDNA levels but suggest that intensified chemotherapy alone may not mitigate recurrence risk, indicating the need for alternative escalation strategies in this high-risk population.